In vitro studies have shown that CNTN1 antibodies can disrupt the interaction between the CNTN1/Caspr1 complex and NF155, altering the structure of the Ranvier node region and contributing to symptoms of CNTN1-related CIDP (34). The gene discussed is CNTN1; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.